Satoru Hara

Ichihara, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Real-world outcomes of venetoclax and azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia (VENUS study).

Real-world outcomes of venetoclax and azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia (VENUS study).

Journal: International journal of hematology

Published: June 15, 2025

Real-World Experience with Venetoclax Treatment for Newly-Diagnosed Acute Myeloid Leukemia in Japan (VENUS Study): An Interim Analysis Focusing on Neutropenia Management.

Real-World Experience with Venetoclax Treatment for Newly-Diagnosed Acute Myeloid Leukemia in Japan (VENUS Study): An Interim Analysis Focusing on Neutropenia Management.

Journal: Oncology and therapy

Published: August 30, 2024

Acute myeloid leukemia with central nervous system involvement successfully treated with gilteritinib

Acute myeloid leukemia with central nervous system involvement successfully treated with gilteritinib

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: April 29, 2024

Epstein-Barr virus-associated lymphoproliferative disorders after BNT162b2 mRNA COVID-19 vaccination

Epstein-Barr virus-associated lymphoproliferative disorders after BNT162b2 mRNA COVID-19 vaccination

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: April 30, 2023

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response.

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response.

Journal: NPJ systems biology and applications

Published: February 22, 2022

Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5 ): The phase 2, multicenter N-Road study.

Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5 ): The phase 2, multicenter N-Road study.

Journal: Cancer medicine

Published: August 21, 2019

CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapy.

CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapy.

Journal: Japanese journal of clinical oncology

Published: February 06, 2017

Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.

Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.

Journal: British journal of haematology

Published: July 19, 2013

Showing 1-8 of 8

Last Updated: 09/26/2026